WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 7 | 8 || 10 |

: , , ...

-- [ 9 ] --

/ ..

49.

, .. , .. , .. // .

2012. 2. . 613.

, .. - / ..

50.

// . . ., 2013. 252 .

, .. 51.

/ .. , .. // . 2014. . X, 4. . 38.

.. / 52.

.. // . .. . .: , 1982. 576 .

, .. 53.

/ .. , .. // .

2014. . 15, 1. . 5354.

/ 54.

.., .., .., ..// . 2011. Vol. 11, 4. C. 3848.

55.

/ .. , .. , .. [ .]// . 2014. 1, 3. . 324.

, .. : . ./ ..

56.

, .. / . .. . .% -, 2004. 304 .

, .. / ..

57.

, .. , . // .: , 1999. 140 .

, .. / 58.

.. , .. // 2- . . .. . .: , 2007. 314 .

( 59.

-)/ .. , .. , .. [ .]// . 2014. . 15, 3. . 4460.

60.

/ .. , . , .. [ .]// .

. 1992. . 64, 7. . 2529.

61.

/ .. , .. , ..

[ .]// . 2014. . X, 4. . 5758.

, .. 62.

/ .. , .. // . 2014. . X, 4. . 4445.

/ .. , .

63.

, .. , .. // . . 2013. .6, 2. . 204209.

: 64.

/ .. , .. , .. , .. // .

. . 2008. - 11-12. . 1931.

, .. , , / .. , ..

65.

, .. // .: -, 2011. 304 .

66.

/ .. , ..

, .. [ .]// . . 2013. . 33, 1. . 54 60.

, .. 67.

: ... - .: 14.01.21/ . , 2014. 47 .

, .. / .. / . ..

68.

(.) : // .:

, 2007. . 724770.

, .. 69.

/ . . .. , . .. // . 2013. . 102 .

, .. (-1, 70.

-, -, -6) / ..

, .. // : . , , 2008. . 97114.

, .. 71.

/ .. , .. // . 2005. . I, 2. . 6369.

() 72.

/ 2 3013 . 183 ()

[ ]// http://www.transfusion.ru/2013/08-29-1.pdf

73. , / ..

, .. , .. [ .]// . 2012. Vol.

13, 3. C. 55.

363 25 2002 74.

.

( 75.

) / ..

, .. , .. [ .]// . - . . 2004. 48 c.

: 76.

/ . ..

. .: , 2012. 1056 .

, .. 77.

/ .. // . 2007. 2. .3136.

() 78.

/ .. , .. , .. [ .]// . 2009. . 2, 3. . 245249.

, .. 79.

/ .. // . . 2012. .5, 4. . 296304.

, .. / . .. , .. // .:

80.

.-., 2011. 240 .

/ . ..

81.

, .. // .: 1960. 963 .

, .. ()/ ..

82.

, .. // .: .. , 2004. . 6394.

, .. , 83.

/ .. , .. , .. // .: -, 2011. 299 .

, .. / ..

84.

// . 2007. . 52, 1. . 3137.

, .. 85.

/ .., .. . .: , 2006.

160 .

, .. / ..

86.

// .: , 2003. 350 .

/ 87.

. .. . , , 2000. 1056 .

/ .. , .. , .. , 88.

.. . .: -, 2012. 271 .

, .. : , 89.

/ .. , .. // . .

. 2003. 5. .4449.

, . / .

90.

// : . 1961. 784 .

: / . .. .

91.

: . . .. , 2014. .

900 .

: / . . ..

92.

. .: - -, 2012. 1184 .

/ . , . / . .

93.

- // .: , 2007. . 369384.

( ) [ 94.

]// http://www.psychol-ok.ru/statistics/fisher/

95. , .. ( 2008 .)/ .. , ..

// . . 2010. .3, 3. . 243251.

, .. / .. , ..

96.

, .. // . 2010. . 3, 3. .

278283.

, 97.

: / .. , .. , .. [ .]// . . . 2006. . 7-8. . 6979.

() / 98.

.. , .. , .. [ .]// . , 2004. 60 c.

, .. :

99.

( )/ .. , ..

// . 2013. 2. . 7782.

100. , .. / .. , .. , .. [ .]// . ., 2006. 28 c.

101. , .. / ..

, .. , .. // .: .., .., .., .. (.) // : , 2003. .

561588.

102. , .. / .. // .

. 2009. . 18, 5. . 5862.

103. 2- (, ) / .. , .. , .. , .. // . 2013. 2. . 2233.

104. / .. , .. , .. [ .]// .. 2006.

7. . 1218.

105. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population/ S. Yang, M. Jun, Z. Hong-Li [et al.]// Int. J. Hematol. 2008. Vol. 88, 2. P. 139144.

106. A new mouse liver specific protein homologous to human antibacterial peptid hepcidin is overexpressed during iron overload/ C. Pigeon, G. Ilyin, B. Courselaud [et al.]/ J. Biol. Hem. 2001. Vol. 276. P. 78117819.

107. A novel protective effect of erythropoietin in the infarcted heart. / C.J. Parsa, A.

Matsumoto, J. Kim [et al.]//J. Clin. Invest. 2003. Vol. 112, 7. P. 9991007.

108. Aapro, M.S. September 2007 update on EORTC guidelines and anemia management with erythropoiesisstimulating agents/ M.S.Aapro, H. Link// Oncologist.

2008. Vol. 13, Suppl. 3. P. 3336.

109. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study/ A. Roghi, M.D. Cappellini, J.C.

Wood [et al.]// Ann. Hematol. 2010. Vol. 89. P. 585589.

110. Absence of functional Epo receptors in normal and cancerous human tissues and cell lines/ S. Elliott, S. Swift, L. Busse [et al.]// Blood. 2011. Vol. 118, 21. P.

3169.

111. Absence of functional EpoR expression in human tumor cell lines/ S. Swift, A.R. Ellison, P. Kassner [et al.]// Blood. 2010. Vol. 115, 21. P. 42544263.

112. Activation of the erythropoietin receptor promoter by transcription factor GATA-1/ L.I. Zon, H. Youssoufian, C. Mather [et al.]// Proc. Natl. Acad. Sci. USA. 1991. Vol. 88, 23. P. 1063810641.

113. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study/ M. Hedenus, G. Birgegrd, P. Nsman [et al.]// Leukemia. 2007. Vol. 21, 4. P. 627632.

114. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients/ M. Martino, E. Oliva, G. Console [et al.]// Support Care Cancer. 2005. Vol. 13, 3. P. 182187.

115. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer/ J.D. Rizzo, M. Brouwers, P. Hurley [et al.]// Blood. 2010. Vol. 116, 20. P. 40454059.

116. An erythropoietin autocrine/ paracrine axis modulates the growth and survival of human prostate cancer cells/ J.Y. Jeong, G. Hoxhaj, A.L. Socha [et al.]// Mol. Cancer Rec. 2009. Vol. 7, 7. P. 11501157.

117. Analysis of the influence of various factors on anemia in patients with lymphoid malignancies/ D. Zupani-Krmek, N. Lang, D. Jurci [et al.]// Acta Clin. Croat. 2011. Vol. 50, 4. P. 495500.

118. Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone with/ without rituximab chemotherapy: results from an observational study/ C. Haioun, A. Salar, R. Pettengell [et al.]// Leukemia & Lymphoma. 2011. Vol. 52. P. 796803.

119. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment/ A. Gaya, A.

Urbano-Ispizua, F. Fernndez-Avils [et al.]// Biol. Blood Marrow Transplant. 2008.

Vol. 14, 8. P. 880887.

120. Anemia in cancer: patophysiology and treatment/ S. Mercadante, V. Gebbia, A.

Marrazzo [et al.]// Cancer Treat. Rev. 2000. Vol. 26. P. 303311.

121. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin/ S.

Hohaus, G. Massini, M. Giachelia [et al.]// J. Clin. Oncol. 2010. Vol. 28, 15. P.

25382543.

122. Anti-Epo receptor antibodies do not predict Epo receptor expression/ S. Elliott, L. Busse, M.B. Bass [et al.]// Blood. 2006. Vol. 107, 5. P. 18921895.

123. Assessing Symptom Distress in Cancer Patients/ C.S. Cleeland, T.R.Mendoza, X.S. Wang, [et al.]//Cancer. 2000. Vol. 89. P. 713.

124. Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19/ M. Budarf, K. Huebner, B. Emanuel [et al.]// Genomics.

1990. Vol. 8, 3. P. 575578.

125. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis/ C.S. Zent, W. Ding, M.S.

Reinalda [et al.]// Leuk. Lymphoma. 2009. Vol. 50, 8. P. 12611268.

126. Baccarrani, M. Evolving concepts in the management of chronic myeloid leukemia recommendations from the an expert panel on behalf of the European Leukemia Net/ M. Baccarrani, G. Saglio, J. Goldman, A. Hochhaus// Blood. 2006. Vol. 108. P. 18091820.

127. Beguin, Y. Prediction of response to optimize outcome of treatment with erythropoietin/ Y. Beguin// Semin. Oncol. 1998. Vol. 25, 3 Suppl 7. P. 2734.

128. Benjamin, R.J. Bacterial contamination/ R.J. Benjamin// Vox Sanguinis. 2013.

Vol. 105, Suppl. 2. P. 3.

129. Blast phase of essential thrombocythemia: A single center study/ F. Passamonti, E. Rumi, L. Arcaini [et al.]// Am. J. Hematol. 2009. Vol. 84, 10. P. 641644.

130. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer/ A.A. Khorana, C.W. Francis, N. Blumberg [et al.]// Arch. Intern. Med. 2008.

Vol. 168, 21. P. 23772381.

131. Blumberg, N. The relation-ship of blood transfusion, tumor staging, and cancer recurrence/ N. Blumberg, C. Chuang-Stein, J.M. Heal// Transfusion. 1990. Vol. 30, 4. P. 291294.

132. Bohlius, J. Twist and shout: one decade of meta-analyses of erythropoiesisstimulating agents in cancer patients/ J. Bohlius, T. Tonia, G. Schwarzer// Acta Haematol. 2010. Vol. 125, 12. P. 5567.

133. Brecher, M.E. Bacterial contamination of blood components/ M.E. Brecher, S.N. Hay// Clin. Microbiol. Rev. 2005. Vol. 18, 1. P. 195204.

134. Broun, J.M. Tumor hypoxia, drug resistans and metastases/ J.M. Broun// J. Natl.

Cancer Invest. 1990. Vol. 82. P. 338339.

135. Cachectin/ tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo/ L.L. Moldawer, M.A. Marano, H. Wei [et al.]// FASEB J. 1989. 3. P. 16371643.

136. Cancer-related fatigue: a practical review/ M.P.O. Campos, B.J. Hassan, R.

Riechelmann, A. Del Giglio// Annals of Oncology. 2011. Vol. 22, 6. P. 1273 1279.

137. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure/ T. Hayashi, A. Suzuki, T.

Shoji [et al.]// Am. J. Kidney. Dis. 2000. Vol. 35, 2. P. 250256.

138. Casadevall, N. Pure red-cell aplasia and antierythropoietin antibodies in patients with recombinant erythropoietin/ N. Casadevall, J. Nataf, B. Viron// N. Engl. J. Med. 2002. Vol. 246. P. 469475.

139. Cazzola, M. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes/ M. Cazzola, M.G. Della Porta, L.

Malcovati// Hematology Am. Soc. Hematol. Educ. Program. 2008. P. 166175.

140. Cella, D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue/ D.

Cella// Semin Hematol. 1997. Vol. 34, 3 Suppl. 2. P. 1319.

141. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in ironoverloaded patients with myelodysplastic syndromes/ H. Ghoti, E. Fibach, D. Merkel [et al.]// Haematologica. 2010. Vol. 95. P. 1433 1434.

142. Characterisation of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells/ J.Y. Jeong, L. Feldman, P. Solar [et al.]// Int.

J. Cancer. 2008. Vol. 122, 2. P. 274280.

143. Characterization of haematological parameters with bortezomibmelphalan prednisone versus melphalanprednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial/ P. Richardson, R.

Schlag, N. Khuageva [et al.]// Br. J. of Haematol. 2011. Vol. 153, 2. P. 212 221.

144. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism/ M.L. Law, G.Y. Cai, F.K. Lin [et al.]// Proc. Nat. Acad. Sci. USA. 1986. Vol. 83, 18. P. 69206924.

145. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice/ J.Y. Jonson, T.A. Waddelow, J. Caro [et al.]// Blood. 1989. Vol. 74. P. 130138.

146. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia/ B.D. Cheson, P.L. Greenberg, J.M.

Bennett [et al.]// Blood. 2006. Vol. 108, 2. P. 419425.

147. Clinical results of recombinant human erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis/ P. Musto, A. Falcone, DArena [et al.]// Eur. J. Haematol. 1997. Vol. 58. P. 314319.

148. Clinical significance of serum erythropoietin levels in patients with multiple myeloma/ M. Takagi, Y. Migamoto, M. Kosaka [et al.]// Rinsho Ketsueki. 1992. Vol. 33. P.11511157.

149. Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders// Y. Zhang, L. Li, L. Nie [et al.]// Zhonghua Xue Ye Xue Za Zhi. 2008. Vol. 29, 2. P.105109.

150. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders/ A. Olivieri, I. Scortechini, D. Capelli [et al.]// Bone Marrow Transplant. 2004. Vol. 34, 8. P. 693702.

151. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetinbeta determined by surface Plasmon resonance and competition binding assay/ M.

Jarsch, M. Brandt, M. Lanzendorfer [et al.]// Pharmacology. 2008. Vol. 81. P.

6369.

152. Control of rHuEPO biological activity: the role of carbohydrate/ S. Elliot, J.

Egrie, J. Browne [et al.]// Exp. Hematol. 2004. Vol. 32, 12. P. 11461155.

153. Correction of disease related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response/ M.P. Siakantaris, M.K. Angelopoulou, N.P. Vassilakopoulos [et al.]// Leuk.

Lymphoma. 2000. Vol. 40, 1-2. P.141147.

154. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalasemia intermedia/ A. Taher, F.E.

Rassi, H. Ismaeel [et al.]// Haematologica. 2008. Vol. 93. P. 15841585.

155. Cross-Cultural Validation of Japanese Functional Assessment of CancerTherapy Anemia (FACT-An)/ A. Yoshimura, K. Kobayashi, H. Fumimoto [et al.]// J.

Nippon Med. Sch. 2004. Vol. 71, 5. P. 314322.

156. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study/ S. Van Belle, C. Karanikiotis, J.L. Labourey [et al.]// Curr. Med. Res. Opin. 2011. Vol. 27, 5. P. 987994.

157. Dammacco, F. Efficacy of epoetin alfa in treatment of anemia of multiple myeloma/ F. Dammacco, G. Castoldi, S. Rodjer// Br. J. Haematol. 2001. Vol. 113, 1. P. 172179.

158. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life/ Oliva E.N., Nobile F., Alimena G. [et al.]// Leuk. Lymphoma. 2010. Vol. 51, 6. P. 10071014.

159. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response/ A.Villegas, B.

Arrizabalaga, C. Fernandez-Lago [et al.]// Curr. Med. Res. Opin. 2011. Vol. 27, 5. P. 951960.

160. Darbepoetin alfa suppresses tumor necrosis factor--induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues/ W.S. Yang, J.W. Chang, N.J. Han, S.K. Park// Free Radic. Biol. Med. 2011. Vol. 50, 10. P. 12421251.

161. Darbepoetin alpha, a long-acting erythropoeitin derivate, does not alter LPS evoked myocardial depression and gene expression of Bax, Bcl-Xs, Bcl-XL, Bcl-2, and TNF-alpha/ P. Brendt, U. Frey, M. Adamzik [et al.]// Shock. 2009. Vol. 31, 1. P. 5054.

162. Davids, M.S. The molecular pathogenesis of myelodysplastic syndromes/ M.S.

Davids, D.P. Steensma// Cancer Biol. Ther. 2010. Vol. 10, 4. P. 309319.

163. Deicher, R. New insights into the regulation of iron homeostasis/ R. Deicher, W.H. Horl// Europ. J. Clin. Inv. 2006. Vol. 36. P. 301308.

164. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factoralpha/ O.A. Tsopra, P.G Ziros, E.D. Lagadinou [et al.]// Acta Haematol. 2009. Vol. 121, 4. P. 187195.

165. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?/ M. Henke, D. Mattern, M. Pepe [et al.]// J. Clin. Oncol. 2006. Vol. 24, 29. P. 47084713.

166. Dreyfus, F. The deleterious of iron overload in patients with myelodysplastic syndroms/ F. Dreyfus// Blood Rev. 2008. Vol. 22 (Suppl. 2). S.2934.

167. Droge, W. Free radicals in the physiological control of cell function/ W. Droge// Physiol. Rev. 2002. Vol. 82. P. 4795.

168. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure/ A.

Quints-Cardama, F.P. De Souza Santos, H. Kantarjian [et al.]// Cancer. 2009. Vol.

115, 17. P. 39353943.

169. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients/ S. Park, C. Kelaidi, R.

Sapena [et al.]// Leuk. Res. 2010. Vol. 34, 11. P. 14301436.

170. Effects of Epoetin- on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy/ C. Christodoulou, U. Dafni, G. Aravantinos [et al.]// Anticancer Research. 2009. Vol. 29. P. 693702.

171. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer/ M.S Aapro, W. Jelkmann, S.N. Constantinescu, B.

Leyland-Jones// Br. J. of Cancer. 2012. Vol. 106, 7. P. 12491258.

172. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study/ M. Hedenus, M. Adriansson, J. San Miguel [et al.]// Br. J. Haematol. 2003. Vol. 122. P. 394403.

173. Efficacy of a combination of human recombinant erythropoietin +13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes/ D. Ferrero, A. Darbesio, V. Giai [et al.]/ Br. J. Haematol. 2009. Vol. 144, 3. P. 342349.

174. Efficacy of Darbepoetin Alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies/ T.J.

Littlewood, J.D. Kallich, J. San Miguel [et al.]// Journal of Pain and Symptom Management. 2006. Vol. 31, 4. P. 317325.

175. Elliot, S. The effect of erythropoietin on normal and neoplastic cells/ S. Elliot, A.M. Sinclair // Biologics: Targets and Therapy. 2012. Vol. 6. P. 163189.

176. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update/ C. Bokemeyer, M.S. Aapro, A. Courdi [et al.]// Eur. J. Cancer. 2007. Vol. 43. P. 258270.

177. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells/ . Hart, J. Grassinger, R. Andreesen, B. Hennemann// Bone Marrow Transplant. 2009. Vol.

43, 3. P. 197206.

178. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial/ M. E. Cabanillas, H.

Kantarjian, D.A. Thomas [et al.]// Cancer. 2012. Vol. 118, 3. P. 848855.

179. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes/ J. Glaspy, J. Crawford, J. Vansteenkiste [et al.]// Br. J. Cancer. 2010. Vol. 102, 2. P. 301315.

180. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells/ S.M. Kumar, H. Yu, D. Fong [et al.]// Melanoma Res. 2006. Vol.

16, 4. P. 275283.

181. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome/ M. Jadersten, L. Malcovati, I.

Dybedal [et al.]// J. Clin. Oncol. 2008. Vol. 26, 21. P. 36073613.

182. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury/ M. L. Brines, P. Ghezzi, S. Keenan [et al.]// Proc. Natl. Acad. Sci. USA.

2000. Vol. 97, 19. P.1052610531.

183. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings/ E. Kaptanoglu, I. Solaroglu, O.

Okutan [et al.]// Neurosurg. Rev. 2004. Vol. 27, 2. P. 113120.

184. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor-mediated neovascularization/ B.D. Westenbrink, E.

Lipsic, P. Van der Meer [et al.]// Eur. Heart J. 2007. Vol. 28. P. 20182027.

185. Erythropoietin in clinical practice: current use, effect on survival, and future directions/ H.S. Oster, M. Hoffman, S. Prutchi-Sagiv [et al.]// IMAJ. 2006. 8. P. 703706.

186. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase/ J.

Cortes, S. O'Brien, A. Quintas [et al.]// Cancer. 2004. Vol. 100, 11. P. 2396 2402.

187. Erythropoietin protects against ischaemic acute renal injury/ D.A. Vesey, C.

Cheung, B. Pat [et al.]// Nephrol. Dial. Transplant. 2004. 19, 2. P. 348355.

188. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemiareperfusion injury/ G.L. Wright, P. Hanlon, K. Amin [et al.]// FASEB J. 2004. Vol.

18, 9. P. 10311033.

189. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span/ P.E.

Sanchez, F.P. Navarro, R.P. Fares [et al.]// J. Comp. Neurol. 2009. Vol. 514, 4. P. 403414.

190. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial/ M. Henke, R. Laszig, C. Rube [et al.]// Lancet. 2003. Vol. 362. P. 12551260.

191. Erythropoietin treatment of anemia associated with multiple myeloma/ H.

Ludwig, E. Fritz, H. Kotzmann [et al.]// N. Engl. J. Med. 1990. Vol. 322. P.

16931699.

192. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature/ F. Cervantes, A.

Alvarez-Larrn, J.C. Hernndez-Boluda [et al.]// Br. J. Haematol. 2004. Vol. 127, 4. P. 399403.

193. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line/ Z.

Shi, V.M. Hodges, E.A. Dunlop [et al.]// Mol. Cancer Res. 2010. Vol. 8, 4. P.

615626.

194. Esquerdo, G. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatiguespecific quality of life questionnaire scores and change in haemoglobin level/ G.

Esquerdo, C. Llorca, J.M.Cervera// Clin. Transl. Oncol. 2011. Vol. 13, 5. P.

341347.

195. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial/ C.P. Miller, K.A. Clowe, K. Valliant-Saunders [et al.]// Stem. Cells. 2009. Vol. 27, 9. P. 23532361.

196. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma/ E.

Katodritou, M. Speletas, K. Zervas [et al.]// Lab. Hematol. 2006. Vol. 12, 1. P.4754.

197. Eve, H.E. Autoimmune haemolytic anaemia associated with mantle cell lymphoma/ H.E. Eve, S.A. Rule// Int. J. Hematol. 2010. Vol. 91, 2. P. 322 325.

198. Expression of erythropoietin and its receptor in neuroblastomas/ H. Sartelet, M.

Fabre, M. Castaing [et al.]// Cancer. 2007. Vol. 110, 5. P. 10961106.

199. Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role hypoxia in tumorigenesis/ Z. Gombos, L. Danihel, V. Repiska [et al.]// Indian J. Pathol. Microbiol. 2011. Vol. 5, 2. P. 273278.

200. Ferritin for the clinician/ M.A. Knovich, J.A. Storey, L.G. Coffman, S.V. Torti// Blood Rev. 2009. Vol. 23. P. 95104.

201. Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS/ S. Park, R. Sapera, C. Keladi [et al.]// Leuc. Res. 2011. Vol. 35. P. 15301533.

202. Five-year follow-up of imatinib therapy for newly diagnosed myeloid leukemia in chronic-phase shows sustained responses and high overall survival/ B.J. Druker, F.

Guilhot, S.G. O'Brien [et al.]// New Engl. J. Med. 2006. Vol. 355. P. 24082417.

203. Fleming, R.E. Ferroprotein mutation in autosomal dominant hemochromatosis:

loss of function, gain in understanding/ R.E. Fleming, W.S. Sly// J. Clin. Inv. 2001. Vol. 108. P. 521522.

204. Frequency and significance of anemia in non-Hodgkins lymphoma patients/ I.

Moullet, G. Salles, N. Ketterer [et al.]// Ann. Oncol. 1998. Vol. 9. P. 11091115.

205. Functional erythropoietin autocrine loop in melanoma/ S.M. Kumar, G. Acs, D.

Fang [et al.]// Am. J. Pathol. 2005. Vol. 166, 3. P. 823830.

206. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells/ A.M. Sinclair, A. Coxon, I. McCaffery [et al.]// Blood. 2010. Vol. 115, 21. P. 42644272.

207. Galinsky, I. Practical management of dasatinib for maximum patient benefit/ I.

Galinsky, S. Buchanan// Clin. J. Oncol. Nurs. 2009. Vol. 13, 3. P. 329335.

208. Gans, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation/ T. Gans// Blood. 2003. Vol. 102, 3. P. 783790.

209. Garcia-Manero, G. Hypomethylating agents and other novel strategies in myelodysplastic syndromes/ G. Garcia-Manero, P. Fenaux// J. Clin. Oncol. 2011.

Vol. 29, 5. P. 516523.

210. Goldberg, S.L. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes/ S.L. Goldberg// Leuk. Res. 2007. Vol.

31, Suppl 3. P. 1622.

211. Gora-Tybor, J. Targeted drugs in chronic myeloid leukemia/ J. Gora-Tybor, T.

Robak// Curr. Med. Chem. 2008. Vol. 15, 29. P. 30363051.

212. Greenberg, P.L. Apoptosis and its role in the in the myelodysplastic syndromes;

implications for disease natural history and treatment/ P.L. Greenberg// Leuk. Res. 1998. Vol. 22. P. 11231136.

213. Gritsaev, S. Selection of candidates for iron chelation therapy (ICT)/ S.

Gritsaev, B. Davaasambuu, N.A. Romanenko// EGM Iron Summit 2013/ Clinical practice strategies and new perspectives in hematology and iron science (Program Book). 2013. P. 30.

214. Hadland, B.K. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms/ B.K. Hadland, G.D. Longmore// J. Clin. Oncol. 2009. Vol. 25. P. 42174226.

215. Hematology Basic Principles and Practice/ R. Hoffman, E.J. Benz, J. Sanford [et al.]// Churchill Livingstone, London. 2000. P. 1294.

216. Henry, D.H. Guidelines and recommendations for the management of anemia in patients with lymphoid malignancies/ D.H. Henry// Drugs. 2007. Vol. 67, 2. P.

175194.

217. Hepcidin: a urinary antibacterial peptide synthesized in the liver/ C.H. Park, E.V. Valore, A.J. Waring [et al.]// J. Biol. Chem. 2001. Vol. 276. P. 78067810.

218. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM/ C. Kelaidi, O. BeyneRauzy, T. Braun [et al.]// Ann. Hematol. 2013. Vol. 92, 5. P. 621631.

219. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution/ A. Azzara, G. Carulli, S.

Galimberti [et al.]// Am. J. Hematol. 2011. Vol. 86, 9. P. 762767.

220. Hoffmann, M. Erythropoiesis stimulating agents/ M. Hoffmann, V. Schwenger// Ther. Umsch. 2011. Vol. 68, 11. P. 650654.

221. Huang, J. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level/ J. Huang, A. Tefferi// Europian Journal of Haematology. 2009.

Vol. 83, 2. P. 154155.

222. Huang, L.J. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor/ L.J. Huang, S.N.

Constantinescu, H.F. Lodish// Mol. Cell. 2001. Vol. 8, 6. P. 13271338.

223. Hunt, J.A. Half-life and rate of synthesis of globin messenger ribonucleic acid.

Determination of half-life messenger ribonucleic acid and its relative synthetic rate in erythroid cells/ J.A. Hunt/ Biochem. J. 1974. Vol. 138, 3. P. 487498.

224. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma/ E. Katodritou, E. Terpos, K. Zervas [et al.]//Ann. Hematol. 2007. Vol. 86, 5. P. 369376.

225. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression/ G. Acs, P.J. Zhang, C.M. Mc Grath [et al.]// Am. J. Pathol. 2003. Vol. 162, 6. P. 17891806.

226. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo/ E.B. Rankin, M.P. Biju, Q. Liu [et al.]// J. Clin. Invest. 2007. Vol. 117. P. 1068 1077.

227. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells/ S. Elliott, L. Busse, I. Mc Caffery [et al.]// J. Immunol. Methods. 2010. Vol. 352. P. 126139.

228. Identification of an intestinal haem transporter/ M. Shayeghi, G.O. LatundeDada, J.S. Oakhill [et al.]// Cell. 2005. Vol. 122. P. 789801.

229. IL-6 mediates hyppoferremia inducting the synthesis of the iron regulatory hormone hepcidin/ E. Nemeth, S. Rivera, V. Gabajan [et al.]// J. Clin. Inv. 2004. Vol. 113. P. 12711276.

230. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia/ S.G. O'Brien, F. Guilhot, R.A. Larson [et al.]// N. Engl. J. Med. 2003. Vol. 348. P. 9941004.

231. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study/ R. A., Larson, B. J. Druker, F. Guilhot [et al.]// Blood. 2008. Vol. 111, 8. P. 4022 4028.

232. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC/ S. Vadhan-Raj, X. Zhou, K. Sizer [et al.]// The Oncologist. 2010. Vol. 15. P. 1359 1369.

233. Implamentation of the full automated, multi-plexed nucleic acid testing at Qingdao blood center, China/ Z. Yand, L. Xu, L. Liu [et al.]// Vox Sang. 2012. Vol. 103, Suppl. 1. P. 152.

234. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia/ B.D. Benites, F. Traina, S.

Duarte Ada [et al.]//Eur. J. Haematol. 2010. Vol. 84, 6. P. 525530.

235. Increased plasma viscosity as a reason for inappropriate erythropoietin formation/ A. Singh, K.U. Eckardt, A. Limmermann [et al.]// J. Clin. Invest. 1993. Vol. 91. P. 251256.

236. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin inmyelodysplastic syndromes? A report on 59 cases/ R. Itzykson, S.

Ayari, D. Vassilief [et al.]// Leukemia. 2009. Vol. 23, 4. P. 673678.

237. Isolation and characterization of genomic and cDNA clones of human erythropoietin/ K. Jacobs, C. Shoemacer, R. Rudersdorf [et al.]// Nature. 1985. Vol. 313. P. 806810.

238. Jabbour, E. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia/ E. Jabbour, M. Deininger, A.

Hochhaus// Leukemia. 2011. Vol. 25. P. 201210.

239. Klein, H.G. Red Blood Cell Transfusion in clinical practice/ H.G. Klein, D.R.

Spahn, J.L. Carson// Lancet. 2007. Vol. 370. P. 415426.

240. Kumral, A. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats/ A. Kumral, N. Uysal, K.

Tugyan [et al.]// Behav. Brain Res. 2004. Vol. 153, 1. P. 7786.

241. Lack of functional erythropoietin receptors of cancer cell lines/ M. Laugsch, E.

Metzen, T. Svensson [et al.]// Int. J. Cancer. 2008. Vol. 122, 5. P. 10051011.

242. Leitch, H.A. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?// H.A. Leitch, L.M. Vickars// Hematology Am. Soc. Hematol.

Educ. Program. 2009. H. 664672.

243. Littelwood, T.J. Influence of the maintenance of hemoglobin of blood on results of treatment of patients with malignant disease/ T.J. Littelwood// Seminars of Oncology. 2001. Vol.28, 2, Suppl. 8. P. 4953.

244. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin +13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival/ E. Cris, C. Foli, R. Passera [et al.]// Br. J. Haematol. 2012. Vol. 158, 1. P. 99107.

245. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib/ F.P.

Santos, Y. Alvarado, H. Kantarjian [et al.]// Cancer. 2011. Vol. 117, 5. P. 982 991.

246. Ludwig, H. Anemia in Cancer patients/ H. Ludwig, E. Fritz// Semn Oncol. 1998. Vol. 25, 3, Suppl. 7. P. 26.

247. Ludwig, H. Anemia in multiple myeloma/ H. Ludwig, G. Pohl, A. Osterborg// Clin. Adv. Hematol. Oncol. 2004. Vol. 2, 4. P. 233241.

248. Ludwig, H. Anemia of hematologic malignancies: what are the treatment options?/ H. Ludwig// Semin. Oncol. 2002. Vol. 29, 3, Suppl. 8. P. 4554.

249. Macdougall, I. Novel erythropoiesis-stimulating agents: a new era in anemia management/ I. Macdougall// Clin. J. Am. Soc. Nephrol. 2008. Vol. 3, 1. P.

200207.

250. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations/ H. Ludwig, K.

Rai, J. Blade [et al.]// Hematol. J. 2002. Vol. 3, 3. P. 121130.

251. Mauro, F.R. Erythropoietin and chronic lymphocytic leukemia/ F.R. Mauro, M.

Gentile, R. Foa// Rev. Clin. Exp. Hematol. 2002. 1. P. 2131.

252. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?/ M.R. Song, J.S. Chung, Y.M. Seol [et al.]// Leuk. Res. 2009. Vol. 33, 11. P. 14591459.

253. Measuring fatigue, and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system/ S.B. Yellen, D.F. Cella, K. Webster [et al.]// J. Pain Symptom Manage. 1997. Vol. 13. P. 6374.

254. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapyinduced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials/ Y. Ohashi, Y. Uemura, Y. Fujisaka [et al.]// Cancer Sci. 2013. Vol. 104,4. P. 481485.

255. Mittelman, M. The implications of anemia in multiple myeloma/ M. Mittelman// Clin. Lymphoma. 2003. Vol. 4, Suppl 1. S. 2329.

256. NCCN Cancer-related Fatigue Panel: National Comprehensive Cancer Network.

Clinical practice Guidelines in Oncology [ ]/ Distress Management Version 1, 2006 / www.nccn.org /.

257. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo/ Y. Sasaki, E. Kjellen, H.

Mineta [et al.]// Acta Oncol. 2009. Vol. 48, 7. P. 10621069.

258. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin Production/ M. Cazzola, Y. Beguin, J. Kloczko [et al.]// Br. J. Haematol. 2003. Vol. 122,3. P. 386393.

259. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study/ Y.

Morishima, M. Ogura, S. Yoneda [et al.]// Jpn. J. Clin. Oncol. 2006. Vol. 36, 10.

P. 655661.

260. One thousand patients with primary myelofibrosis: the mayo clinic experience/ A. Tefferi, T.L. Lasho, T. Jimma [et al.]// Mayo. Clin. Proc. 2012. Vol. 87, 1. P. 2533.

261. Orphanos, G.S. Cardiotoxicity induced by tyrosine kinas inhibitors/ G.S.

Orphanos, G.N. Ioannidis, A.G. Ardavanis// Acta Oncol. 2009. Vol. 48, 7. P.

964970.

262. Osterborg, A. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy/ A. Osterborg, J.L. Steegmann, A.

Hellmann// Br. J. Haematol. 2007. Vol. 136, 5. P. 736744.

263. Oxford Handbook of Clinical Haematology/ D. Provan, C.R.J. Singer, T. Baglin, I. Dokal// Oxford University Press, Third edition (2009). 2012. 820 P.

264. Papayannopoulono, T. Biology of erythropoiesis, erythroid maturation and differentiation/ T. Papayannopoulono, J. Abkowitz, A. DAndrea/ In: Hoffman R., Benz E.J., Shattil S.J. [et al.] editors Hematology Basic Principals and Practice. 3 rd ed.

Philadelphia: Churchill Livingston. 2000. P. 202219.

265. Patients with cancer/ A. Nicolaides, J.Fareed, A.K. Kakkar [et al.]// Clin. Appl.

Thromb Hemost. 2013. Vol. 19, 2. P. 172176.

266. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer/ D.L. Hershman, D.L. Buono, J. Malin [et al.]// J. Natl. Cancer Inst. 2009. Vol. 101, 23. P. 16331641.



Pages:     | 1 |   ...   | 7 | 8 || 10 |
 

:

13.00.01 , : , ,...

. () 03.02.08 , .. 2015...

14.02.02 : ...

- 03.01.06 ( ) , .. 2014 .....

IN VITRO 03.02.03 : ...

( CLETHRIONOMYS) - 03.02.08 : .. 2015 .. 1. ...

03.03.05 , : .. 2015 1 ...

03.02.08 () : ...

- - 03.02.08 ( ) : ...

: 06.02.02 , , , :...

03.02.14 2015 ..3 I. . 1.1....

03.02.02 : , 2015 1 2 2.1 ...

( ) 25.00.36 ( ) - - 201...

( , , ) 14.03.09 , ...

- - 06.01.05. : ...

- 06.02.10 , ; 06.02.08 , . ...

BETULA L. 03.02.14 : , .. 20 .. 1 . 1.1 ...

() - 03.03.04 , , ...

: , , 03.01.06 ( ...

- 25.00.08 ,...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .